注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Arbutus Biopharma Corp是一家临床阶段的生物制药公司。该公司专注于开发针对特定病毒疾病治疗方法的病毒学能力。该公司的重点领域包括乙型肝炎病毒(HBV)、SARS-CoV-2和其他冠状病毒。在HBV方面,该公司正在开发一种核糖核酸干扰(RNAi)治疗剂、口服衣壳抑制剂、口服PD-L1抑制剂和口服RNA失稳剂,旨在通过抑制病毒复制、减少表面抗原和重新唤醒免疫系统,为慢性HBV感染(cHBV)患者提供功能性治疗。其先导化合物AB-729是唯一具有免疫再觉醒证据的RNA干扰疗法,目前正在多个II期临床试验中进行评估。该公司正在进行一项药物研发计划,旨在识别治疗冠状病毒(包括SARS-CoV-2)的口服活性药物。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Frank M. Torti | 42 | 2018 | Independent Chairman of the Board of Directors |
Kyong-Mi Chang | - | - | Member of Scientific Advisory Board |
Ulrike Protzer | - | - | Member of Scientific Advisory Board |
Adrian Di Bisceglie | - | - | Member of Scientific Advisory Board |
Keith S. Manchester | 56 | 2015 | Independent Non-Executive Director |
William T. Symonds | 56 | 2015 | Chairman of Scientific Advisory Board |
Fabien Zoulim | - | - | Member of Scientific Advisory Board |
James R. Meyers | 59 | 2018 | Independent Director |
Daniel D. Burgess | 62 | 2017 | Independent Director |
Charles M. Rice | - | - | Member of Scientific Advisory Board |
Scott A. Biller | 68 | - | Member of Scientific Advisory Board |
Richard C. Henriques | 68 | 2014 | Independent Non-Executive Director |
Michael J. McElhaugh | 49 | 2018 | Co-Founder, Interim President, CEO & Director |
Melissa V. Rewolinski | 53 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核